Status:

COMPLETED

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Lead Sponsor:

Celltrion

Conditions:

Healthy Subjects

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

This study is a Phase 1, 2-Part, Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Three Subcutaneous Injection Formulations of ...

Detailed Description

CT-P43 is being developed as a proposed biosimilar of Stelara (ustekinumab). This study will be conducted in 2 parts. In Part 1, subjects will be enrolled and randomized in a 1:1 ratio to receive a si...

Eligibility Criteria

Inclusion

  • Healthy male subjects, between the ages of 18 and 55 years.
  • Subject with a BMI between 18.5 and 29.9 kg/m2. Weight between 60 to 100 kg.
  • Subject must agree to use medically acceptable methods of contraception consistent with local regulations during the course of the study and for 18 weeks after administration of the study drug.
  • Subject is informed and able to understand the full nature and purpose of the study, including possible risks and side effects, and is given ample time and opportunity to read and understand this information.

Exclusion

  • Subject has a prohibited medical history and/or current condition.
  • Subject is planning to father a child or donate sperm within 18 weeks after the administration of the study drug (Day 1).
  • Subject previously received any biologic agents
  • In the opinion of the investigator, the subject is not eligible for the study participation for any reason.
  • Subject is vulnerable.

Key Trial Info

Start Date :

August 3 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 24 2021

Estimated Enrollment :

271 Patients enrolled

Trial Details

Trial ID

NCT04428814

Start Date

August 3 2020

End Date

February 24 2021

Last Update

August 5 2021

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Auckland Clinical Studies Limited

Grafton, Auckland, New Zealand, 1010

2

Christchurch Clinical Studies Trust Limited

Christchurch, Canterbury, New Zealand, 8011

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects | DecenTrialz